key: cord-0821029-ro2ze3p6
authors: Noske, G. D.; Nakamura, A. M.; Gawriljuk, V. O.; Fernandes, R. S.; Lima, G. M. A.; Rosa, H. V. D.; Pereira, H. D.; Zeri, A. C. M.; Nascimento, A.A. F. Z.; Freire, M. C. L. C.; Oliva, G.; Godoy, A. S.
title: A Crystallographic Snapshot of SARS-CoV-2 Main Protease Maturation Process
date: 2021-01-22
journal: bioRxiv
DOI: 10.1101/2020.12.23.424149
sha: 702977c1e9dd68b7bbaf8b2ef38d11bbba8bead1
doc_id: 821029
cord_uid: ro2ze3p6

SARS-CoV-2 is the causative agent of COVID-19. The dimeric form of the viral main protease is responsible for the cleavage of the viral polyprotein in 11 sites, including its own N and C-terminus. Although several mechanisms of self-cleavage had been proposed for SARS-CoV, the lack of structural information for each step is a setback to the understanding of this process. Herein, we used X-ray crystallography to characterize an immature form of the main protease, which revealed major conformational changes in the positioning of domain-three over the active site, hampering the dimerization and diminishing its activity. We propose that this form preludes the cis-cleavage of N-terminal residues within the dimer, leading to the mature active site. Using fragment screening, we probe new cavities in this form which can be used to guide therapeutic development. Furthermore, we characterized a serine site-directed mutant of the main protease bound to its endogenous N and C-terminal residues during the formation of the tetramer. This quaternary form is also present in solution, suggesting a transitional state during the C-terminal trans-cleavage. This data sheds light in the structural modifications of the SARS-CoV-2 main protease during maturation, which can guide the development of new inhibitors targeting its intermediary states.

M pro and IMT M pro demonstrate to be active and able to recognize and cleave the fluorogenic substrate ( Fig. 1) , with Km values of 16.4 ± 2.3 μM and 34.3 ± 2.2 μM, respectively. IMT M pro exhibited only 6% of the catalytic efficiency compared with mature M pro . As previously reported, the M pro N-terminal is fundamental for dimerization and any additional residues would reduce or even abolish its activity 9, [16] [17] [18] . As expected, C145S M pro has only shown residual activity (Fig. 1) . All three M pro constructs exhibited similar thermal-stability profiles, indicating similar folding (Fig. 1) .

Analysis in solution using SEC-MALS suggests that M pro behaves as a dimer in the tested conditions, as expected 11 . For IMT M pro , the additional residues at N-terminal seem to prevent dimerization completely. For C145S M pro , however, the additional residues allow the protein to adopt multiple conformational states ranging from monomers to tetramers (Fig. 1) .

Despite the site-direct mutagenesis of the C145S M pro , the enzyme exhibited residual proteolytic activity which allowed us to observe self-processing by SDS-PAGE in the course of two days. Despite the efficiency of M pro , its addition to the reaction does not seem to enhance significantly the rate of self-cleavage, suggesting cis-cleavage as main mechanism of N-terminal cleavage (Fig. 1 ).

Crystal structure of M pro M pro was crystallized in several conditions and its X-ray structure was determined at 1. 46 Å in C21 space group. All 306 residues were refined at the electron density to a final Rwork/Rfree of 0.16/0.18, with 99% of Ramachandran in favored positions (Table S2 ). The crystal asymmetric unit contains one monomer which could be symmetry expanded to the biological dimer, following the same pattern of the majority of known structures deposited in PDB (r.m.s.d of 0.2 Å vs PDB 5RGG, for all Cα 306). The M pro protomers are formed by three domains (DI, DII and DIII), with its catalytic region located at the double-barreled DII 9 (Fig. S2 ).

The crystal structure of IMT M pro at 1.6 Å was determined using 3 merged datasets ( Fig  S3, S4 , Table S1) in P212121 space group, with two molecules in the asymmetric unit, packed in similar shape to the known biological unit of M pro . The structure was refined to a final R work /R free of 0.20/0.22, with 97% of Ramachandran in favored positions (Table S2 ). In the recent published structures of GM-M pro , both apo and ligand-complexes exhibited minor differences with the mature form 16 . However, in our structure there are distinguishable differences in the overall structure, especially in the position of DIII helices (Fig. 2) . Although IMT M pro asymmetric unit resembles the biological dimer form of native protein, PISA 19 analysis indicate that the dimer packing is unstable in solution, with an interface area of 1,256 Å 2 (vs 1,557 Å of M pro ), calculated free energy ΔG of -13.4 kcal/mol (vs -14.9 kcal/mol of M pro ) for 26 potential hydrogen bonds (vs 49 of M pro ) and 5 potential salt bridges (vs 10 of M pro ).

While IMT M pro DI and DII are less affected by the N-terminal insertion (r.m.s.d of 0.34 Å vs Mpro mat for Cα of 1-184), DIII appears to adopt a more open conformation relative to M pro (r.m.s.d of 1.33 Å for Cα of 201-301) (Fig. 2) , with the interfacing residues Ala285 at a distance of 10 Å in the IMT M pro (vs 5.2 Å in M pro ) (Fig. S5 ). This conformation is more accentuated at chain A where the electron density of the N-terminal insertion is clearly visible in the model. For this chain, the N-terminal insertion pushes chain A helices αF and αH further of chain B active site, opening a cleft for Phe140 rises to the surface of the molecule, leading to major conformation alterations of the chain B active site souring residues, such as Glu166, Pro168 and Gln189 ( Fig. 2 and S6). The plasticity of SARS-CoV-2 M pro active site was already reported when apo X-ray structures collected at cryo and room temperatures were compared 20 , and its expected given the broad spectrum of endogenous substrates that M pro is expected to process. However, the IMT M pro revealed major structural alterations in the oxyanion hole, likely affecting enzyme processing. Despite the significant changes of the active site, relative position of the catalytic dyad Cys145-His41 remains unchanged in this form (Fig. 2) .

Recently, a small-fragment library of more than 1,250 unique fragments were screened against SARS-CoV-2 M pro , identifying 74 high-value fragment hits, including 23 non-covalent and 48 covalent hits in the active site, and 3 hits close to the dimerization interface 21 . In here, we applied the same technique to probe new druggable cavities in IMT M pro . Although the difference in scale of our experiment, we were able to identify five distinguishable sites in this form of the protein (Fig. 3) . Site #1 is the active site of chain A, in which fragment f2xe03 was identified interacting with Glu166 N and Cys145 S. Interesting, a unique cavity marked as Site #3 was identified in our experiments, bound to fragment f2xg02 by Arg4 main chain O. That cavity lies between the interface of chains A and B, and is not present in M pro which adopt a more closed conformation. This new site and fragment could serve as an anchor for development of new inhibitors targeting M pro dimerization process, a mode of action that was too date only theorized 22 . Details about data processing and statistics are given in Table S3 .

The tetramer peaks were crystallized and X-ray structure determined at 2.8 Å and Rwork/Rfree of 0.20/0.24 (Table S2) , revealing a new crystal form in which N-terminal chain B residues are trimmed in the active site of chain A, occupying subsites S1-S5 (Fig. 4) . Despite the site directed mutagenesis of the catalytic cysteine to serine, electron density shows that Gln0 and Ser1 are noncovalently bound in the amino region, clearly indicating that the N-terminal cis-cleavage was completed. At the S1 subsite, Gln0 NE2 interacts with Glu166 OE1 by a hydrogen bound (2.7 Å), while Gln0 form interacts with Ser145 in the position of the native oxyanion hole (Fig. 4, Fig S8-S9 ). To accommodate the hydrophobic sidechain of Leu-1 at P2, Met49 and Met165 are pushed further of each other (Fig. S10 ), leading to a more opened groove of this subsite relatively to the apo-state, explaining the ability of this subsite to accommodate a variety of hydrophobic side chain residues, such as Leu, Met, Ile, Val and Phe 6, 23 . Yet, from the eleven endogenous recognition sites of coronaviruses, S2 Leu carrying sequences are the ones in which M pro display higher catalytic efficiency, highlighting the importance of this conformation for drug design. At subsites S3-S5, the interactions of Val-2, Ala-3 and Ser-4 are mainly maintained by hydrogen bounds between the polar residues of protein and peptide side chains (Fig. 4) , which explains the ability of M pro to recognize a large variety of chain sequences at those positions.

The crystal structure of C145S M pro revealed another important step in the maturation process of M pro . At the same time that chain B N-terminal additional residues are processed by chain A, its C-terminal residues (301-306) are almost 180 o twisted from its original position (Fig. S11) and trimmed in the active site of a symmetric related chain B (Fig. 4) a phenomenon that was also recently described by another group in both native and in a C145A M pro mutant 24 . During this event, two C145A M pro dimers appear to be linked by the interaction of the C-terminal and a respective active site, assuming a tetrameric conformation (Fig. 5 ). Within the active site, Gln306 occupies the respective position of Gln0 at S1, while S2 is occupied by Phe305, increasing the distance between Met49 and Met165 relatively to chain A bound to N-terminal (Fig. S10) . As the N-terminal residues, subsites S3-S5 interactions with C-terminal are mainly maintained by hydrogen bounds between main chains (Fig 4) .

M pro is firstly produced as the Nsp5 domain of the viral polyproteins before they are proteolytically processed into 15 or 16 non-structural proteins 12 . Immediately after translation, the immature form of M pro would contain both N and C-terminal insertions that need self-processing to generate the mature form of the enzyme 13 .

The biochemical assays of IMT M pro revealed that a minor insertion at the N-terminal produces a protein form that behaves as a monomer in solution and its almost depleted of enzymatic activity, even though the general folding remains similar to the full mature form. The same process occurs to C145S M pro with native N-terminal inserted residues, although, in this case, a slow cleavage of the N-terminus results in the formation of dimers overtime (Fig. 1) . It is important to highlight that when M pro is added to C145S M pro , the N-terminal cleavage and dimer formation does not seem to be enhanced, strongly suggesting that this initial maturation step is a cis-cleavage event. This is in agreement with the model proposed by Li and colleagues (2010) in which two M pro form a transient dimer that is stabilized by the binding the N-terminal site of its substrate (another M pro in polyprotein) and further cleave to free its N terminus 14 .

After the active site region is matured (or even concomitantly), dimeric M pro , C-terminal seem to assume an unusual twisted position (Fig. S11) , allowing it to be docked into the active site of another mature or half-mature M pro dimer (Fig. 4) . In this step, the trans-cleavage processing of the C-terminal residues would serve as an anchor for a transitory tetrameric state of the protein, herein captured with the construct of the mutant C145S M pro with the processing of the N-terminal residues (Fig. 5) . As a result, full mature M pro is produced and its ready to process other parts of the viral polyprotein. During all those maturation processes, both M pro active site and surface undergo significant conformational changes, which could guide targeted drug development ( 

Figures S1-S13

Tables S1-S5

References (25-48) Scheme S1 Overview of the tetrameric intermediary formed by C145S M pro during self-processing. Chain A is colored as yellow surface, chain B as cyan surface. Trans-cleavage M pro partner is show as green cartoon. N-terminal residues are depicted as blue spheres, and C-terminal residues are depicted as red spheres. 

The viral cDNA template (GenBank MT126808.1), kindly provided by Dr. Edison Durigon (University of São Paulo, São Paulo, Brazil), was synthetized using the SCRIPT One-Step RT-PCR kit (Cellco Biotec) and random hexamers primers. For production of IMT M pro , coding region of M pro (residues 3264-3569) was amplified using primers: Fw 5' CAGGGCGCCATGAGTGGTTTTAGAAAAATGGCATTC 3' and Rv 5' GACCCGACGCGGTTATTGGAAAGTAACACCTGAGAC 3', and the sequence was inserted into the pET_M11 vector, which encodes an N-terminal 6xHis-tag followed by a TEV protease cleavage site (ENLYFQ↓GAM), using the LIC method (25), forming the plasmid pET_M11-IMT-M pro . To obtain the mature form of M pro , native N-terminal residues (GAMSAVLQ↓SGFRK) were inserted into pET_M11-IMT-M pro by inverse PCR using primers: Fw: 5' GCTGCAGAGTGGTTTTAGAAAAATGGCATTC 3' and Rv: 5' ACGGCTGACATGGCGCCCTGAAAATA 3'. Amplified product was treated with T4 Polynucleotide Kinase (PNK, Thermo Fischer Scientific) and T4 Ligase (Cellco Biotec), forming plasmid pET_M11-M pro . For C145S M pro construct, pET_M11-M pro was used as template for inverse PCR with primers Fw 5' CCTTAATGGTTCATCTGGTAGTG 3' and Rv 5' AATGAACCCTTAATAGTGAAATTGG 3'. The PCR product was digested with DpnI (NEB), followed by treatment with PNK and T4 DNA ligase, forming the pET_M11-C145S-M pro . All plasmids were transformed in DH5α E. coli competent cells. All PCRs were conducted with FastPol (Cellco Biotech). Positive clones were selected and confirmed by sequencing. Schematics of constructs are given in Fig. S1 .

For protein production, E. coli BL21 cells were transformed with respective plasmids and cultured in ZYM-5052 (26) 

After expression, a large amount of IMT M pro had its 6xHis-tag cleaved by autoproteolytic process. The small fraction of 6xHis tagged protein was removed from the lysate using Ni-NTA resin (Qiagen). The cleaved protein was purified by adding 1 M ammonium sulfate to the cell lysate followed by incubation on ice for 10 min. The precipitated protein was recovered by centrifugation at 12,000 x g for 30 min at 4 °C, resuspended in gel filtration buffer (20 mM Tris pH 7.8, 150 mM NaCl, 1 mM EDTA, 1 mM DTT) and purified by size-exclusion chromatography using a HiLoad 26/100 Superdex 200 column (GE Healthcare) pre-equilibrated with gel filtration buffer. Purified fractions were aliquoted, flash-frozen and stored at -80 °C for enzymatic assays and crystallization. For crystallization, protein was concentrated to 14 mg.mL -1 using 10 kDa MWCO centrifugal concentrators (Vivaspin, Sartorius). Protein concentrations were determined using the measured absorbances at 280 nm and the theorical extinction coefficient of 32,890 M -1 .cm -1 . Protein purity was analyzed by SDS-PAGE (Fig. S1 ).

M pro was purified similar to IMT M pro , with an additional step of cation exclusion chromatography. After the size exclusion chromatography, the protein was buffer exchanged to 20 mM Tris pH 8.0, 1 mM DTT, and then injected into a Mono-Q 5/50 GL column (GE Healthcare). Protein was eluted using a linear gradient of a buffer containing 20 mM Tris pH 8.0, 1 M NaCl and 1 mM DTT. Finally, fractions containing the purified protein were buffer exchanged to gel filtration buffer. Purified fractions were aliquoted and protein was concentrated and quantified similarly to IMT M pro (Fig. S1 ).

For C145S M pro , protein was purified by immobilized metal chromatography (IMAC) using a 5 mL HisTrap FF column (GE Healthcare). After column washing with buffer A (20 mM Tris pH 7.8, 150 mM NaCl, 25 mM Imidazole), protein was eluted with buffer A supplemented with 250 mM imidazole. Sample was buffer exchanged using a 5 mL HiTrap desalting column (GE Healthcare) equilibrated with buffer A. To remove the 6xHis-tag, 2 mg of TEV protease and 4 mM DTT were added to the sample and incubated for 16 h at 4 ºC. Next day, non-cleaved protein and TEV were removed by a second step of IMAC in buffer A. Finally, the protein was purified by size-exclusion chromatography using a HiLoad 16/60 Superdex 75 column (GE Healthcare) equilibrated with gel filtration buffer. Purified fractions were aliquoted, and protein was concentrated and quantified as described for other constructions (Fig. S1 ).

Crystallization screening was performed with the sitting drop vapor diffusion method in 96 -well plates using a Phoenix Liquid Handling System-Gryphon LCP (Art Robbins Instruments) and commercially available kits at 20 °C. For M pro , crystals appeared after 1 day in 0.1 M Bis-Tris pH 6.5, 25% PEG 3,350, which were cryoprotected using the reservoir solution and 30% PEG 400. Crystals of IMT M pro were observed in several conditions. After optimization, crystals grown in 0.1 M MES pH 6.5, 10% 2-propanol, 20% PEG Smear Low (BCS Screen, Molecular Dimensions) were used as seeds for the diffraction crystals, obtained in 0.1 M MES pH 6.7, 5% DMSO, 8% PEG 4,000 (21) . Crystals of C145S M pro were obtained after 3 days in 0.1 M phosphate/citrate, pH 5.5, 20% v/v PEG Smear High (BCS Screen, Molecular Dimensions).

During the initial commissioning phase (July to October 2020) the MANACA (MAcromolecular Micro and NAno CrystAllography)(27) beamline adopted an emergency commissioning plan to deliver the basic instrumentation to perform data collection of SARS-CoV-2 related samples. Thus, during this period, the beamline has operated on a fixed-energy regime (9 keV) with manual crystal mounting, single-axis goniometry, beam flux estimated to be about 1·10 11 ph/s/10 mA at 9.15 keV and adjustable beam size from about 18 (h) x 20 (v) µm² to 100 (h) x 80 (v) µm² (FWHM). This project was the first external user session at MANACA beamline and the first operating beamline at Sirius (SIRIUS, Brazil). The focus was optimised to 61 (h) x 48 (v) µm² at sample position (Fig. S3) . Even without the full capabilities, the beamline opening was very important to SARS-CoV-2 structural biology studies.

X-ray data for apo IMT M pro was collected from three isomorphous independent crystals, that were processed by XDS via autoPROC (28, 29) . Data herein was used for confirm reliability of the beamline (Fig. S5 and Table S1 ). Datasets were then scaled and merged using Aimless (30) , and the resulting dataset was used for structural determination of IMT M pro by molecular replacement with Phaser (31) using PDB 5RGQ as template. Model was refined with COOT(32) and BUSTER (33) at 1.6 Å and deposited under the code 7KFI.

X-ray data for mature M pro and C145S M pro were processed by XDS via autoPROC (28, 29) and scaled using Aimless (30) . Mature M pro and C145S M pro were solved by molecular replacement with Phaser (31) using template models 5RGQ and 7KFI, respectively. Mature M pro and C145S M pro were refined with COOT(32) and phenix.refine (34) , and are respectively deposited under the codes 7KPH (at 1.4 Å) and 7KVG (at 2.8 Å). Details of data processing parameters and statistics are given in Table S2 .

For the fragment screening of IMT M pro , we used the settled plates fragment libraries of FragMAXlib (Talibov et al., to be published) and F2XEntry (35, 36) . In those plates, the content of each drop-well was resuspended in 1.0 µL of 0.1 M MES pH 6.7, 5% DMSO (v/v), 8% PEG 4,000 (w/v), 30% PEG 400 (w/v), and crystals were added afterwards. After 4 h soaking at room temperature, crystals were manually harvested and flash cooled for data collection.

During the commissioning phase of MANACA, 166 of those crystals were tested, leading to 77 usable datasets. To analyze the data, a simplified version of FragMAXapp was configurated in our laboratory end-station computer. Within FragMAXapp, restrictions libraries were generated by phenix.eLBOW (37) using rm1 force field for geometry optimization, and datasets were processed through autoPROC/STARANISO or DIALS via XIA2 (28, 38, 39) . Molecular replacement and initial refinement were performed using DIMPLE (40) using PDB 7KFI as template. To highlight electron density of weak binding events, map averaging and statistical modelling were performed by PanDDA software (41) . Models were refined with COOT(32) and phenix.refine (34) . Details of data processing and refinement statistics are given in Table S3 .

Activity assays All enzymatic assays were carried out using FRET-based substrate DABCYL-KTSAVLQ↓SGFRKM-E(EDANS)-NH2 in assay buffer (20 mM Tris pH 7.3, 1 mM EDTA, 1 mM DTT). M pro , IMT M pro and C145S M pro assays were performed at final concentration of 0.14 μM, 0.3 µM and 0.3 µM, respectively. Prior to reactions, enzymes were incubated in assay buffer at 37 °C for 10 min, followed by substrate addition. To determine the kinetics parameters (Km, Vmax and kcat), the substrate was diluted to a range of concentrations from 100 μM to 0.78 μM. Initial velocity was derived from the slope of linear phase of each time-curse reaction, and Michaelis-Menten fitting was obtained using Origin Pro 9.5.1 Software (OriginLab). Fluorescence measures were performed in SpectraMax Gemini EM Microplate Reader with λexc/λemi of 360/460 nm, every 30 s over 60 min at 37º C. All assays were performed in triplicates.

To test C145S M pro auto-cleavage activity, 6xHis-tagged C145S M pro was buffer exchanged in 20 mM Hepes pH 7.3, 100 mM NaCl, 1 mM DTT. Two reactions were prepared for comparison, one containing 10 µM C145S M pro and other containing 10 µM C145S M pro and 5 nM of mature M pro . Aliquots of each reactions were collected for the period of 40h. Samples were analyzed by SDS-PAGE on a 12.5% SDS polyacrylamide gel.

For differential scanning fluorimetry assays (DSF), SYPRO Orange at 5X final concentration was added to protein diluted to 25 μM protein in gel filtration buffer. Denaturation curves was obtained ranging temperature from 25°C to 75°C increasing one degree per cycle and fluorescence was measured in the end of each cycle. Experiment was conducted in a qPCR system Mx3000P (Agilent). The melting temperature was obtained using the Boltzmann fitting on Origin Pro 9.5.1 Software (OriginLab).

The in solution oligomeric states of the purified samples were evaluated by size exclusion chromatography coupled with multi-angle light scattering (SEC-MALS) in running buffer composed by 20 mM Tris-HCl pH 7.8 and 100 mM NaCl. For that, 50 µL of each M pro construct at concentration of 10 µM were injected in a Waters 600 HPLC system (Waters) coupled in-line with an UV detector, a miniDAWN TREOS multi-angle light scattering apparatus (Wyatt Technology), a column Superdex 200 Increase 10/300 GL (GE Healthcare), and a refractive index detector Optilab T-rEX (Wyatt Technology). The light-scattering detectors were normalized with bovine serum albumin (Sigma-Aldrich). Data were collected and analyzed with the ASTRA 7 integrated software provided by Wyatt. The flow rate used was 0.5 mL/min. Results are summarized in Table S4 . Scheme S1. Schematic showing steps of SARS-CoV-2 M pro maturation process. The immature monomeric form of M pro form an intermediary dimer during cis-cleavage of N-terminal. With a mature N-terminal, the M pro is then transcleaved by the dimeric association with another dimer, producing full mature M pro . M pro chain A and B are shown in blue and salmon, respectively. N and C terminals are marked in green and blue, respectively. Polyprotein is shown as black lines. (46) . 2 CC1/2 is the correlation coefficient determined by two random half data sets (47) 3 Rwork = ∑hkl│Fo(hkl) -Fc(hkl)│/ ∑hkl Fo(hkl). Rfree was calculated for a test set of reflections (5%) omitted from the refinement. 4 Clashscore is the number of clashes calculated for the model per 1000 atoms (48) . 

A novel coronavirus from patients with pneumonia in China

A new coronavirus associated with human respiratory disease in China

The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

Biosynthesis, Purification, and Substrate Specificity of Severe Acute Respiratory Syndrome Coronavirus 3C-like Proteinase

Identification of key interactions between SARS-CoV-2 main protease and inhibitor drug candidates

Coronavirus main proteinase (3CLpro) Structure: Basis for design of anti-SARS drugs

Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved a-ketoamide inhibitors

Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur

GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease

Activation and maturation of SARS-CoV main protease

Mechanism of the maturation process of SARS-CoV 3CL protease

Maturation mechanism of severe acute respiratory syndrome (SARS) coronavirus 3C-like proteinase

Liberation of SARS-CoV main protease from the viral polyprotein: N-terminal autocleavage does not depend on the mature dimerization mode

Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease

Structure of coronavirus main proteinase reveals combination of a chymotrypsin fold with an extra α-7 helical domain

Production of Authentic SARS-CoV Mpro with Enhanced Activity: Application as a Novel Tag-cleavage Endopeptidase for Protein Overproduction

Inference of macromolecular assemblies from crystalline state

Structural plasticity of SARS-CoV-2 3CL Mpro active site cavity revealed by room temperature X-ray crystallography

Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease

Targeting the Dimerization of the Main Protease of Coronaviruses: A Potential Broad-Spectrum Therapeutic Strategy

SARS-CoV-2 Mpro inhibitors and activitybased probes for patient-sample imaging

Crystallographic structure of wild-type SARS-CoV-2 main protease acyl-enzyme intermediate with physiological C-terminal autoprocessing site

Ligation-independent cloning of PCR products (LIC-PCR)

Protein production by auto-induction in high density shaking cultures

The Sirius project

Data processing and analysis with the autoPROC toolbox

How good are my data and what is the resolution?

Phaser crystallographic software

Features and development of Coot

Exploiting structure similarity in refinement: Automated NCS and target-structure restraints in BUSTER

Towards automated crystallographic structure refinement with phenix.refine

F2X-Universal and F2X-Entry: Structurally Diverse Compound Libraries for Crystallographic Fragment Screening

FragMAX: the fragment-screening platform at the MAX IV Laboratory

Electronic ligand builder and optimization workbench (eLBOW): A tool for ligand coordinate and restraint generation

DIALS: Implementation and evaluation of a new integration package

Advances in automated data analysis and processing within autoPROC , combined with improved characterisation, mitigation and visualisation of the anisotropy of diffraction limits using STARANISO

Overview of the CCP4 suite and current developments

A multi-crystal method for extracting obscured crystallographic states from conventionally uninterpretable electron density

Iterative-build OMIT maps: map improvement by iterative model building and refinement without model bias

Improvements to the APBS biomolecular solvation software suite

Ligplot: A program to generate schematic diagrams of protein-ligand interactions

Polder maps: Improving OMIT maps by excluding bulk solvent

How good are my data and what is the resolution?

Linking crystallographic model and data quality

MolProbity: all-atom structure validation for macromolecular crystallography